InvestorsHub Logo
Followers 44
Posts 3174
Boards Moderated 2
Alias Born 01/18/2016

Re: None

Monday, 05/01/2023 10:18:51 AM

Monday, May 01, 2023 10:18:51 AM

Post# of 3582
Enrollment rate: ~125/mo.

Cassava Sciences is evaluating its lead drug candidate, simufilam, in people with Alzheimer’s disease. Over 1,244 patients with mild-to-moderate Alzheimer’s disease are now enrolled in our Phase 3 program of simufilam, up from over 1,000 enrolled patients as of February 28, 2023. The target enrollment is approximately 1,750 patients.

https://www.sec.gov/Archives/edgar/data/1069530/000117184323002712/exh_991.htm

All my postings are verified and approved by my dog.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SAVA News